Pelvic floor disorders and sexual function in gynecologic cancer survivors: a cohort study

Published:September 27, 2010DOI:


      The purpose of this study was to assess the prevalence of pelvic floor disorders and sexual function in survivors of gynecologic cancer.

      Study Design

      We surveyed survivors of gynecologic cancer (survivors) and women seeking gynecologic care (control patients) who were >30 years old. All survivors were disease- and treatment-free for ≥1 year. Validated questionnaires were used to evaluate pelvic floor disorders.


      One hundred eight control patient and 260 survivor questionnaires were completed. A high prevalence of pelvic floor disorders was observed in both groups; 56% of control subjects and 70% of survivors reported moderate to severe urinary incontinence (P > .05). Survivors were more likely to experience fecal incontinence (42% vs 32%; P = .02). Survivors reported less sexual desire (P = .04) and less ability to climax (P = .04), despite no difference in dyspareunia.


      Fecal incontinence and sexual dysfunction are significant problems in survivors of gynecologic cancer.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • US Cancer Statistics Working Group
        United States cancer statistics: 2004 incidence and mortality.
        Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, Atlanta2007
        • Rose P.G.
        Concurrent cisplatin-based radiotherapy and chemoradiation for locally advanced cervical cancer: results of a randomized Gynecologic Oncology Group study.
        N Engl J Med. 1999; 340: 1144-1153
        • Sandvik H.
        • Hunskaar S.
        • Seim A.
        • Hermstad R.
        • Vanvik A.
        • Bratt H.
        Validation of a severity index in female urinary incontinence and its implementation in an epidemiologic survey.
        J Epidemiol Commun Health. 1993; 47: 497-499
        • Jorge J.M.N.
        • Wexner S.D.
        Etiology and management of fecal incontinence.
        Dis Colon Rectum. 1993; 36: 77-97
        • Lukacz E.S.
        • Lawerence J.M.
        • Buckwalter J.G.
        • Burchette R.J.
        • Nager C.W.
        • Luber K.M.
        Epidemiology of prolapsed and incontinence questionnaire: validation of a new epidemiologic survey.
        Int Urogynecol J Pelvic Floor Dysfunct. 2005; 16: 272-284
        • Nygaard I.
        • Barber M.D.
        • Burgio K.L.
        • et al.
        Prevalence of symptomatic pelvic floor disorders in US women.
        JAMA. 2008; 300: 1311-1316
        • Rogers R.G.
        • Coates K.W.
        • Kammerer-Doak D.
        • Khalsa S.
        • Qualls C.
        A short form of the pelvic organ prolapsed/urinary incontinence sexual questionnaire (PISQ-12).
        Int Urogynecol J Pelvic Floor Dysfunct. 2003; 14: 164-168
        • Green M.S.
        Sexual dysfunction following vulvectomy.
        Gynecol Oncol. 2000; 77: 73-77
        • Wenzel L.
        Quality of life in long-term cervical cancer survivors.
        Gynecol Oncol. 2005; 97: 310-317
        • Dunberger G.
        • Lind H.
        • Steineck G.
        • et al.
        Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls.
        Eur J Cancer. 2009; 46: 606-615
        • Del Priore G.
        • Taylor S.Y.
        • Esdaile B.A.
        • et al.
        Urinary incontinence in gynecologic oncology patients.
        Int J Gynecol Cancer. 2005; 15: 911-914